Symptoms and Outcomes of COVID-19 in Elderly Recipients of Influenza and COVID-19 Vaccines

All published articles of this journal are available on ScienceDirect.

RESEARCH ARTICLE

Symptoms and Outcomes of COVID-19 in Elderly Recipients of Influenza and COVID-19 Vaccines

Fatemeh Mohammadkhah1 Seyed Amirhossein Moslehi2 Fatemeh Larijani3 Arash Ziapour4 Fakhreddin Chaboksavar5 Hamidreza Asaeiyan6 Kamiar Hossein Ashrafi7 Zahra Fotokian8 , * Open Modal
Authors Info & Affiliations
The Open Public Health Journal • 16 Oct 2023 • RESEARCH ARTICLE • DOI: 10.2174/0118749445249950230921065742
Previous Article | Next Article

Abstract

Background:

Health providers and policymakers aim to prevent or reduce the severity of disease outcomes globally.

Objective:

The present study aimed to explore the outcomes and common symptoms of COVID-19 in the elderly population vaccinated against influenza and COVID-19 in hospitals of Ramsar and Tonekabon cities in Iran.

Methods:

To participate in the present cross-sectional descriptive study, 11 qualified subjects were selected through a census. The data collection instruments included the “Demographic and clinical questionnaire” and “Registration form of sampled patients with acute disease syndrome”. The data were analyzed in SPSS 24 using descriptive statistics (frequency).

Results:

The average age of the participants was 70.63±5.85 years. As the results showed, mild cardiovascular symptoms were found in 6 participants (54.5%), lower respiratory system symptoms in 5 (45.5%), nervous system symptoms in 4 (36.4%), and auxiliary symptoms in 4 (36.4%). No cardiac, renal, blood or central nervous system outcomes were observed in the elderly, and the mortality rate was 0%. The findings also showed a reduction in clinical symptoms and severity of outcomes, an improvement in clinical findings, and no mortality among the elderly.

Conclusion:

The present findings supported measures aimed at increasing the coverage of influenza and COVID-19 vaccination in people, especially the elderly.

Keywords: COVID-19, Influenza vaccines, COVID-19 vaccines, Symptoms, Patient outcome assessment, Influenza.

1. INTRODUCTION

COVID-19 has turned into a global issue. Until 19 November 2021, a total number of 254,847,065 people had been infected with COVID-19, and 5,120,712 died as a result in the world. In Iran, 6,057,893 people were infected with the disease, and 128,531 died of the infection [1, 2]. Thus, health providers and policymakers attempt to prevent or reduce the severity of the disease outcomes on a global scale [3-6]. One way to prevent or reduce the severity of disease outcomes is vaccination. COVID-19 vaccination for high-risk groups has already begun in many countries [7], but still COVID-19 inflicts many people worldwide [1, 8]. Many countries have prioritized vaccinating high-risk populations, such as the elderly and those at a greater risk of infection, such as the medical staff [7]. There are concerns that the confluence of COVID-19 and seasonal influenza in autumn and winter may lead to a high mortality rate and challenge the health system [9]. Therefore, it is necessary to identify factors that may increase the burden of disease in society and take measures in this field [10-13]. Influenza vaccination for high-risk populations has raised concerns about the coincidence of vaccination with the spread of COVID-19 and its clinical outcomes and the resultant mortalities [14]. However, studies in recent months evidenced the reduced clinical outcomes of COVID-19 in influenza vaccine recipients [15-19]. Several researchers believe that high vaccine coverage will reduce the spread of influenza and improve the efficiency and performance of the health system to provide services to control COVID-19 [20-22]. Preventive vaccines are the most effective countermeasure against influenza virus infection and its pandemic [23, 24]. In Iran, there were concerns about the possibility of influenza spreading simultaneously with the spread of COVID-19. On 3 October 2020, Iran Ministry of Health and Medical Education (MOHME) announced the influenza vaccination guidelines to the affiliated organizations. Due to the limited supply of influenza vaccine and the allocated human influenza vaccine quota, this guideline gives instructions on prioritizing the recipients of the seasonal influenza vaccine [25-28]. Then, the question raised was whether the use of the flu vaccine reduced the common symptoms and severity of the outcomes of COVID-19. It is necessary to conduct more research on healthcare systems and different communities to explore the prevalence of the outcomes of COVID-19 in recipients of trivalent influenza and COVID-19 vaccines. In their research, Ruscio et al. showed that simultaneous vaccination against COVID-19 and influenza could help prevent respiratory and cardiovascular diseases and reduce mortalities [29, 30]. In another study, Ragni et al. found a significant negative relationship between receiving the influenza vaccine and COVID-19 diagnosis. Yet, receiving the influenza vaccine was ineffective in improving the outcomes of COVID-19 [18, 19, 31-33].

Then, the question raised was whether the influenza vaccine could reduce the typical symptoms and severity of the outcomes of COVID-19 in the elderly. The immune system undergoes many changes through ageing, known as immune aging. These changes affect many cellular and molecular elements of both the innate and acquired immune systems and their coordination in response to infections. These make the elderly population particularly vulnerable to new infectious diseases. Immune aging, characterized by a decrease in the ability to develop an adequate immune response to infection and sustainability to pro-inflammatory diseases, is a major factor in the elderly’s susceptibility to COVID-19 [34-36]. The elderly over 65 years of age are known as the high-risk groups. They are more vulnerable than other age groups and need special care and attention. Social isolation, social distance, and quarantine measures to prevent the spread of COVID-19 raised concerns about the elderly’s general health [37]. This disease adversely affects the physical and social health of the elderly, who already suffer immunodeficiency, low activity, and improper nutrition. Nurses play an important role in preventing the virus infection, treating and caring for the elderly, and providing rehabilitation after discharge [38, 39]. The outcomes of COVID-19 in the elderly include neurological, cardiovascular, respiratory, digestive, skeletal-muscular, behavioral, and mental-psychological changes, changes in nutritional status, pain, lung involvement, and mortality [36, 40].

There are contradictory findings in the existing literature in different countries and different service providers. In Iran, there is a lack of similar research on the prevalent outcomes of COVID-19 in recipients of trivalent inactivated influenza and COVID-19 vaccines. Most of the 60 to 80-year-old residents of Ramsar were vaccinated against both influenza and COVID-19 in health centers. Thus, the present study aimed to explore the outcomes and typical symptoms of COVID-19 in the elderly recipients of influenza and COVID-19 vaccines in Ramsar and Tonekabon cities in Iran.

2. METHODS AND MATERIALS

2.1. Design of Study and Sample Selection

The present research was cross-sectional and descriptive in type. The case study included the hospitals of Ramsar and Tonekabon cities in Iran. The research population consisted of all hospitalized patients aged 60-80 years in Ramsar and Tonekabon hospitals. The data collection began after the project was approved by the Research Council of Babol University of Medical Sciences and the research ethics committee. A census sampling method was used in this study. The inclusion criteria were: having visited the hospital due to COVID-19 infection, the age of 60-80 years, having received trivalent influenza and COVID-19 vaccines, having received two doses of COVID-19 vaccine, a proper interval between receiving two COVID-19 vaccinations (21 days for Spontik, 28 days for Sinopharm, and 3 months for Estrazinka), and entrance to the study two weeks after the second vaccination. The exclusion criterion was the incompleteness of more than two-thirds of the records and registration forms of patients hospitalized with COVID-19.

The necessary data were then extracted from the registration forms of the sample suffering from an acute respiratory disease in hospitals. The necessary information about the history of receiving the COVID-19 vaccine was collected from the health headquarters of Ramsar and Tonekabon. The census included the time span between the beginning of the national vaccination program (3 October) in health centers and hospitals until the sampling (26 May 2022). Since the majority of elderly residents of Ramsar (aged 60 to 80) were vaccinated against influenza and COVID-19 in health centers, the research population included all elderly residents (60-80 years) of Ramsar and Tonekabon. The data were collected using the information registration form of sampled patients suffering from acute respiratory distress syndrome (ARDS) (for COVID-19 patients) in Ramsar and Tonekabon hospitals. This study form was completed when the COVID-19 patients were admitted to hospitals.

2.2. Instrumentation

There were two data collection instruments: “The Demographic and Clinical Questionnaire” and “The Registration Form of Sampled Patients with Acute Respiratory Disease” as described below:

2.2.1. Demographic and Clinical Questionnaire

It includes information about age, sex, job, education level, place of residence, marital status, type of influenza vaccine, and type of COVID-19 vaccine.

2.2.2. Registration form of Sampled Patients with Acute Respiratory Disease

It includes information about receiving the influenza vaccine, receiving the COVID-19 vaccine, history of comorbidities, outcomes of COVID-19 (respiratory support, central nervous outcomes, cardiovascular outcome, renal and blood outcomes [e.g., polynephritis/cystitis, ATN, uremia, DIC, bleeding (due to thrombocytopenia)], pulmonary outcome, determination of lung involvement, duration of hospitalization, and mortality rate), clinical symptoms of COVID-19 [(e.g., typical symptoms, lower respiratory tract symptoms, cardio-respiratory symptoms), and auxiliary symptoms (e.g., muscle pain-cramping, anorexia, chilling, skin bruising, joint pain, headache, nausea and vomiting, runny nose/sneezing, red eyes, diarrhea, fever and cough, abnormal hearing, conjunctival redness, radiological signs)].

2.3. Data Analysis

The data were analyzed using relevant descriptive statistics (frequency). A multivariate regression model was used to test the relationship between trivalent influenza and COVID-19 vaccination with the prevalence of typical symptoms and outcomes of COVID-19. However, the multivariate regression analysis was not applicable due to the small number of eligible subjects and the limited number of those in the statistical columns, and the results were not reported. SPSS 24 was used for data analysis.

3. RESULTS

A total of 11 elderly people with a mean age of 70.63±5.85 years in the age range of 60-78 years were examined in the study. All the elderly had no history of traveling in the past two weeks. 90.9% (n=10) of patients were hospitalized during the sampling (Table 1).

Table 1.
Demographic characteristics of the elderly who received influenza and COVID-19 vaccines in Ramsar and Tonekabon cities.
Demographic Variable Levels Number Percent(%)
gender men 7 63.6
women 4 36.4
Level of Education Under high school diploma 7 63.6
High school diploma 3 27.3
Academic 1 9/1
place of residence City 7 63.6
Village 4 36.4
marital status Single 2 18.2
married 9 81/8
Underlying disease yes 11 100
no 0 0
The frequency of infection with COVID-19 1 9 81.8
2 2 18.2
Type of influenza vaccine received Trivalent 10 90.9
Quadrivalent 1 9.1
Type of COVID-19 vaccine received AstraZeneca 1 9.1
Sputnik 1 9.1
Sinopharm 9 81.8
Patient's status during sampling Hospitalized 10 90.9
Outpatient 1 9.1
History of travel in the last two weeks yes 0 0
no 11 100
age (years); mean(SD) 70.63±5.85
Table 2.
Determining the clinical symptoms of COVID-19 infection in the elderly who received influenza and COVID-19 vaccines in Ramsar and Tonekabon cities.
Clinical Symptoms Of Covid Levels Number Percent(%)
Key symptoms no 4 36.4
Cough 3 27.3
Fever and cough 4 36.4
Lower respiratory tract symptoms no 6 54.5
Shortness of breath 2 18.2
Difficult breathing 3 27.3
Cardiovascular symptoms No 5 45.5
Chest discomfort 6 54.5
Nervous system symptoms No 7 63.6
The feeling of confused/dizzy 2 18.2
Sleepiness 2 18.2
Auxiliary symptoms No 7 63.6
Muscle pain and bruising 3 27.3
Muscle pain, joint pain, and runny nose 1 9.1

The results showed that key symptoms (63.6 percent), cardiovascular symptoms (54.5 percent), lower respiratory tract symptoms (45.5 percent), nervous system symptoms (36.4 percent), and auxiliary symptoms (4 The highest prevalence of key symptoms of covid-19 is among the elderly. So that in the key symptoms, 27.3 percent of the elderly had cough symptoms and 36.4 percent had fever and cough symptoms (Table 2).

36.4% of the elderly needed respiratory support; Also, the results showed that heart, kidney, blood and central nervous system complications were not observed in the elderly with covid-19 who received influenza vaccine and covid vaccine. Also, the results show that 9.1% of the elderly with covid had pulmonary ARDS (Table 3).

The results showed that in terms of previous disease history, 45.4% of the elderly had one disease. Also, the results show that 54.5% of the elderly had a long history of aspirin use and all the elderly had no history of prophylaxis. Corona disease was detected in 27.3% of the elderly through CT scan findings (Table 4).

Table 3.
Determining the outcome of infection with COVID-19 in the elderly who received influenza and COVID-19 vaccines in Ramsar and Tonekabon cities.
Outcome Of COVID-19 Levels Number Percent(%)
Respiratory support yes 4 36.4
no 7 63.6
Cardiac outcome no 11 100
yes 0 0
kidney and blood outcome no 11 100
yes 0 0
Central nervous system outcome no 11 100
yes 0 0
Pulmonary outcome no 10 90.9
ARDS 1 9.1
Table 4.
Determining the imaging findings, previous disease history, drug use history, and death and discharge information of elderly people who received influenza and COVID-19 vaccines in Ramsar and Tonekabon cities.
Variables Levels Number Percent (%)
History of previous diseases One disease 5 45.4
Two diseases 4 36.3
More than two diseases 2 18.3
History of prophylaxis yes 11 100
no 0 0
History of drug use no 5 45.5
Long-term consumption of aspirin 6 54.5
Imaging findings no 8 72.7
CT Scan 3 27.3
Discharge Status yes 11 100
no 0 0
Patient status at discharge Relative improved 5 45.5
Improved 6 54.5
Death yes 0 0
no 11 100
Number of hospitalization days Less than 3 3 27.3
3-5 5 45.4
More than 5 3 27.3

4. DISCUSSION

The present study aimed to explore the outcomes and common symptoms of COVID-19 in the elderly recipients of influenza and COVID-19 vaccines in Ramsar and Tonekabon. As the results showed, cardiovascular, lower respiratory system, nervous system, and auxiliary symptoms were, respectively, observed in the participants at the rates of 27.3 and 54.5 percent.

The involvement of several organs, including the liver, digestive system, and kidney, was reported in SARS in 2003 and recently in patients with COVID-19 [31]. Even though the respiratory and immune systems are the main targets of COVID-19, there is also acute kidney damage and protein excretion in the urine [31]. As the literature shows, neurological, cardiovascular, and respiratory outcomes have been observed in the elderly with COVID-19 [41-43]. This contradictory finding shows that it may be possible to reduce the severity of symptoms and the involvement of vital organs in patients with COVID-19 by vaccinating them with two vaccines, influenza and COVID-19.

In light of the present findings, the clinical symptoms in the elderly included mild symptoms such as fever, cough, shortness of breath, difficulty breathing, chest discomfort, confusion/dizziness, sleepiness, muscle pain and bruises, joint pain, and runny nose. Similar studies during the pandemic in 2019-2020 and before vaccination for COVID-19 showed that besides the symptoms mentioned above, there were more extensive and severe symptoms such as smell and hearing disorders, digestive disorders (e.g., nausea and vomiting, diarrhea, stomachache, taste and smell disorders), anxiety and poor quality of sleep, low lymphocytes, skin rashes, abnormality in chest CT scan images and even death [34, 41]. Liu et al. reported that the most common symptoms of COVID-19 in the elderly were fever, cough, sputum, involvement of the lung lobes, and decreased lymphocytes [41]. These findings suggest that more research is needed to answer the question of whether it is possible to prevent the severity of symptoms of these two diseases (influenza and COVID-19) by vaccinating the elderly against the two diseases.

The frequency of COVID-19 outcomes in the elderly recipients of influenza and COVID-19 vaccines in Ramsar showed that a few elderly participants needed respiratory support. This result was consistent with another study by Fink et al. (2020). This study clinically examined subjects with a history of inactivated trivalent influenza vaccination, hospitalized with a definite diagnosis of COVID-19, and having received the influenza vaccine. The research findings indicated that vaccinated subjects needed invasive respiratory services less than the control [34]. In a study by Lee et al., the mortality rate, severity of symptoms, and the need for respiratory aids were higher in the elderly over 65 years of age [45]. However, in another study by Hosseini Damiri et al., fewer patients needed respiratory support. The statistical difference might be due to the different research populations, sample size, study time, and different history of chronic diseases [46].

The results also showed that cardiac, renal, blood and central nervous system outcomes were not observed in the elderly recipients of influenza and COVID-19 vaccines, and only 1 participant had the pulmonary outcome of acute respiratory distress syndrome (ARDS). These findings are consistent with a body of research [47-51]. This disease has numerous short-term or long-term complications in different body organs. Lung involvement is suggested as the main cause of mortality, and complications are frequently reported, such as lung fibrosis, secondary bacterial or fungal infections, cardiac involvement (myocarditis and pericarditis), and vascular complications such as pulmonary embolism [46]. The results of other studies have reported the COVID-19 outcomes in the elderly, including neurological, cardiovascular, respiratory, and renal-blood outcomes [41, 52, 53]. In light of the present findings and the existing literature, vaccination can be a useful method to prevent many complications of COVID-19.

The present study showed that the mortality rate was 0% in patients with a history of comorbidities (one disease, two, and more than two diseases). Furthermore, the results of studies by Arab et al. [54], Salari et al. and Firouzi et al. indicated an increase in the mortality outcome in people with a history of chronic disease and COVID-19, probably due to the different sample size, research population, and the history of vaccination [55, 56]. Daoust reported that the mortality rate of COVID-19 was higher in the elderly [57]. As reported by Zaki et al., the severity of symptoms and mortality of COVID-19 were higher in the elderly with a history of chronic diseases [58]. The inconsistent findings of these studies show that vaccination against COVID-19 and influenza can help prevent the severe outcomes of the disease, including mortality in patients with comorbidities.

As the present findings showed, COVID-19 was diagnosed in 27.3% of the elderly through CT scan findings. Another study by Sun et al. found abnormalities in the chest CT scan images of 96% of patients infected with COVID-19, probably due to the different history of vaccination and the time setting of research [59]. In another study by Alian et al., the percentage of lung involvement was 75.6% (within a range of 0-25%), 29.22% (within a range of 25-50%), and 27.20% (within a range of more than 75%) [60]. In a study by Shafiei et al., per broncho vascular features were significantly observed in hospitalized patients with COVID-19. Furthermore, an increase in patient age increased the number of lobes involved in the lung. The consolidation level was significantly higher in hospitalized patients with fever or myalgia. A significant increase was observed in linear opacities of hospitalized patients with diarrhea or nausea, indicating the high and severe involvement of lungs in COVID-19 patients in 2020 and before the national vaccination in Iran [61]. These data indicated the lung involvement in hospitalized patients before vaccination against COVID-19 and the usefulness of COVID-19 vaccination in preventing lung involvement.

As the results showed, more than half of the elderly had a complete recovery at discharge, and the other half had a partial recovery. In a study by Fink et al., COVID-19 patients with a recent experience of inactivated influenza vaccination had significantly better clinical outcomes than unvaccinated patients in Brazil [61]. In a study by Caspi et al., the severity of disease and mortality were lower in the elderly vaccinated against COVID-19 [62]; hence, it may be possible to take effective steps to improve the clinical findings of hospitalized patients by vaccinating the elderly against the two diseases, influenza and COVID-19.

Many studies have focused on the clinical characteristics of Covid-19 patients, and information about the factors affecting the severity and lethality of the disease among the elderly is still limited [63] According to the findings, the duration of hospitalization decreased, and the mortality rate was 0% in patients. The results are consistent with a study by Fang et al. (2020), which showed a lower mortality rate of COVID-19 patients vaccinated with Brazil's trivalent inactivated influenza vaccine. The vaccinated subjects had a 16% lower mortality rate than the control group [64]. In another study, Marín-Hernández et al. (2020) showed a significant negative relationship between the mortality rate induced by COVID-19 and receiving the influenza vaccine in the elderly [41]. The mortality rate of the elderly recipients of the COVID-19 vaccine was lower in the study conducted by Parra et al. [65].

The usefulness of vaccination against influenza and COVID-19 to prevent the mortality of the elderly with COVID-19 should be taken seriously according to the present findings because age is a risk factor for COVID-19 and mortality in the elderly [61].

4.1. Limitations

The limitations of the study include the limited sample size and the impossibility of generalizing the results. It was impossible to test the regression of the symptoms and outcomes of COVID-19 on the participants’ demographic variables due to the limited sample size. The study was descriptive and it was impossible to control all the results' determinants.

4.2. Suggestions

It is suggested to conduct further research on healthcare systems and different populations to answer the question about the prevalence of symptoms and outcomes of COVID-19 in recipients of trivalent influenza and COVID-19 vaccines. It is also suggested to test the relationship between the regression of symptoms and the outcome of COVID-19 on participants’ demographic variables.

CONCLUSION

There are always concerns that the confluence of COVID-19 and seasonal influenza in the fall and winter may lead to significant mortality and impose high costs on the health system. Therefore, it is necessary to explore the relevant factors that may increase the disease burden on society and take the required measures. Health providers and policymakers in the world aim to prevent or reduce the severity of disease outcomes. The most effective countermeasure against influenza virus and COVID-19 infection is to use preventive vaccines. The results of the present study showed reduced clinical symptoms and less severe outcomes, improved clinical results, and less mortality in the elderly with a history of vaccination against influenza and COVID-19. Therefore, the present findings support measures taken to increase the coverage of vaccination against influenza and COVID-19 in the public, especially the elderly population.

LIST OF ABBREVIATIONS

COVID-19 = Corona Virus-19
ARDS = Acute Respiratory Distress Syndrome

AUTHORS’ CONTRIBUTION

All authors participated and approved the study design. FM, ZF, and FC contributed to the design study, AZ, SAM, and FL collected the data and analyzed it by KHA and HRE. The final report and manuscript were developed by FM, ZF, and AZ. All authors read and approved the final draft.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

The study was approved by the Research Ethics Committee of Babol University of Medical Sciences (#IR.MUBABOL.HRI.REC.140.178). Written informed consent was obtained from all group members. Consent to submission was all co-authors, as well as the corresponding author - tacitly or explicitly - at the institute/organization where the work has been carried out before the work was submitted.

HUMAN AND ANIMAL RIGHTS

No animals were used in this research. All human participants were used in accordance with the ethical standards of the committee in charge of human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2013.

CONSENT FOR PUBLICATION

Consent was obtained from all participants of this study.

STANDARDS OF REPORTING

STROBE Guidelines were followed in this study

AVAILABILITY OF DATA AND MATERIALS

The datasets used in the study are available from the corresponding author [Z.F] upon reasonable request.

FUNDING

None.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

All participants in this study are appreciated.

REFERENCES

1
WHO. Advice on the Use of Masks in the Context of COVID-19: Interim Guidance, 5 June 2020, World Health Organization. 2020. Available from: https://apps.who.int/iris/ bitstream/handle/10665/332293/WHO-2019-nCov-IPC_Masks-2020.4-eng.pdf
2
Sahebi A, Yousefi A, Abdi K, et al. The prevalence of post-traumatic stress disorder among health care workers during the COVID-19 pandemic: an umbrella review and meta-analysis. Front Psychiatry 2021; 12: 764738.
3
Nobakht S, Shirdel A, Molavi-Taleghani Y, Doustmohammadi MM, Sheikhbardsiri H. Human resources for health: A narrative review of adequacy and distribution of clinical and nonclinical human resources in hospitals of Iran. Int J Health Plann Manage 2018; 33(3): 560-72.
4
Baniasadi H, Hosseini SS, Abdollahyar A, Sheikhbardsiri H. Effect of massage on behavioural responses of preterm infants in an educational hospital in Iran. J Reprod Infant Psychol 2019; 37(3): 302-10.
5
Sheikhbardsiri H, Esamaeili Abdar Z, Sheikhasadi H, Ayoubi Mahani S, Sarani A. Observance of patients’ rights in emergency department of educational hospitals in south-east Iran. Int J Hum Rights Healthc 2020; 13(5): 435-44.
6
Abdollahyar A, Baniasadi H, Doustmohammadi MM, Sheikhbardesiri H, Yarmohammadian MH. Attitudes of Iranian nurses toward spirituality and spiritual care. J Christ Nurs 2019; 36(1): E11-6.
7
Beaumont P. Covid-19 vaccine: who are countries prioritising for first doses. Guardian 2020; p. 18.
8
Heidarijamebozorgi M, Jafari H, Sadeghi R, Sheikhbardsiri H, Kargar M, Gharaghani MA. The prevalence of depression, anxiety, and stress among nurses during the coronavirus disease 2019: a comparison between nurses in the frontline and the second line of care delivery. Nurs Mid Stud 2021; 10(3): 188.
9
Lawrence O, Gostin J, Center L. The dual epidemics of COVID-19 and influenza: Vaccine acceptance, coverage, and mandates. JAMA 2020; 324(4): 335-6.
10
Sheikhbardsiri H, Mousavi SH, Doustmohammadi MM, Karimi M, Salahi S. The effect of educational workshop on emergency department nurses’ self-efficacy in patient training. J Educ Health Promot 2019; 8: 136.
11
Molavi-Taleghani Y, Ebrahimpour H, Sheikhbardsiri H. A proactive risk assessment through healthcare failure mode and effect analysis in pediatric surgery department. J Compr Pediatr 2020; 11(3): e56008.
12
Davarani ER, Tavan A, sheikhbardsiri H, Amiri H, Sahebi A. Response capability of hospitals to an incident caused by mass gatherings in southeast Iran. Injury 2022; 53(5): 1722-6.
13
Ziapour A, Zokaei A, Kahrizy F. A Theoretical Study of the Standing of Social Investment in the Health Sector. Soc Sci 2016; 11(15): 3682-7.
14
Grohskopf LA, Liburd LC, Redfield RR. Addressing influenza vaccination disparities during the COVID-19 pandemic. JAMA 2020; 324(11): 1029-30.
15
Odone A, Bucci D, Croci R, Riccò M, Affanni P, Signorelli C. Vaccine hesitancy in COVID-19 times. An update from Italy before flu season starts. Acta Biomed 2020; 91(3): e2020031.
16
Richmond H, Rees N, McHale S, Rak A, Anderson J. Seasonal influenza vaccination during a pandemic. Hum Vaccin Immunother 2020; 16(9): 2219-21.
17
Fink G, Orlova-Fink N, Schindler T, et al. Inactivated trivalent influenza vaccination is associated with lower mortality among patients with COVID-19 in Brazil. BMJ Evid Based Med 2021; 26(4): 192-3.
18
Marín-Hernández D, Schwartz RE, Nixon DF. Epidemiological evidence for association between higher influenza vaccine uptake in the elderly and lower COVID‐19 deaths in Italy. J Med Virol 2021; 93(1): 64-5.
19
Ragni P, Marino M, Formisano D, et al. Association between exposure to influenza vaccination and COVID-19 diagnosis and outcomes. Vaccines 2020; 8(4): 675.
20
Control CfD, Prevention. Flu vaccination coverage, United States, 2018–19 influenza season. 2019.
21
Gostin LO, Salmon DA. The dual epidemics of COVID-19 and influenza: vaccine acceptance, coverage, and mandates. JAMA 2020; 324(4): 335-6.
22
Yoosefi Lebni J, Pavee S, Saki M, Ziapour A, Ahmadi A, Khezeli M. Determinants of observing health protocols related to preventing COVID-19 in adult women: A qualitative study in Iran. Front Public Health 2022; 10: 969658.
23
Krammer F. Emerging influenza viruses and the prospect of a universal influenza virus vaccine. Biotechnol J 2015; 10(5): 690-701.
24
Nejaddadgar N, Jafarzadeh M, Ziapour A, Rezaei F. Determinants of COVID-19 vaccine acceptance in Ardabil: A web-based survey health educ. Health Promot 2022; 10(2): 221-5.
25
Alzoubi H, Alnawaiseh N, Al-Mnayyis A, Abu- Lubad M, Aqel A, Al-Shagahin H. COVID-19 - knowledge, attitude and practice among medical and non-medical university students in Jordan. J Pure Appl Microbiol 2020; 14(1): 17-24.
26
NeJhaddadgar N, Ziapour A, Zakkipour G, Abbas J, Abolfathi M, Shabani M. Effectiveness of telephone-based screening and triage during COVID-19 outbreak in the promoted primary healthcare system: a case study in Ardabil province, Iran Iran J Public Health 2020; 30(5): 1301-6.
27
Yoosefi Lebni J, Irandoost SF, Xosravi T, et al. Explaining the problems faced by Iranian housewives during the COVID-19 quarantine period, and their adaption strategies: A qualitative study. Womens Health 2021; 17: 1-13.
28
Yoosefi Lebni J, Abbas J, Moradi F, Salahshoor MR, Chaboksavar F, Irandoost SF. How the COVID-19 pandemic effected economic, social, political, and cultural factors: A lesson from Iran Int J Soc Psychiatry 2021; 67(3): 298-300.
29
Ruscio BA, Hotez P. Expanding global and national influenza vaccine systems to match the COVID-19 pandemic response Vaccine 2020; 38(50): 7880.
30
NeJhaddadgar N, Razie T, Javad YL, Isabela AM, Arash Z. Exploring the barriers in maintaining the health guidelines amid the COVID-19 pandemic: A qualitative study approach. INQ 2022; 59: 1-11.
31
Parra PNB, Atanasov V, Whittle J, et al. The effect of the COVID-19 pandemic on the elderly: Population fatality rates, COVID mortality percentage, and life expectancy loss. Elder Law J 2022; 30: 33-80.
32
Yoosefi Lebni J, Yazdani V, Ziapour A, Chaboksavar F, Khosravi B, Dehghan AA. The impacts of the COVID-19 pandemic on child marriage in Iran. J Health Soc Sci 2022; 7(3): 256-9.
33
Yoosefi Lebni J, Ziapour A, Mehedi N, Irandoost SF. The role of clerics in confronting the COVID-19 crisis in Iran. J Relig Health 2021; 60(4): 2387-94.
34
Moradi M, Navab E, Sharifi F, Namadi B, Rahimidoost M. The effects of the COVID-19 pandemic on the elderly: A systematic review. Salmand Iran J Ageing 2021; 16(1): 2-29.
35
Yoosefi Lebni J, Irandoost SF, Mehedi N, Sedighi S, Ziapour A. The role of celebrities during the COVID-19 pandemic in Iran: Opportunity or threat? Disaster Med Public Health Prep 2022; 16(4): 1292-3.
36
Safi-Keykaleh M, Aliakbari F, Safarpour H, et al. Prevalence of postpartum depression in women amid the COVID‐19 pandemic: A systematic review and meta‐analysis. Int J Gynaecol Obstet 2022; 157(2): 240-7.
37
Khanizadeh T, Omranifard V, Khanizadeh S. The outcomes of COVID-19 epidemic crisis on the elderly: A review study. Majallah-i Danishkadah-i Pizishki-i Isfahan 2021; 39(622): 292-302.
38
Gença F, Uslu A. Nursing approaches and their effect on the health of elderly with COVID-19. Int J Emerg Trends Soc Sci 2020; 4(3): 100-10.
39
Das S, Arun P, Rohilla R, Parashar K, Roy A. Anxiety and depression in the elderly due to COVID-19 pandemic: A pilot study. MECP 2021; 28(1): 67.
40
Jamebozorgi MH, Karamoozian A, Bardsiri TI, Sheikhbardsiri H. Nurses burnout, resilience, and its association with socio-demographic factors during COVID-19 pandemic. Front Psychiatry 2022; 12: 803506.
41
Dayaramani C, De Leon J, Reiss AB. Cardiovascular disease complicating COVID-19 in the elderly. Medicina 2021; 57(8): 833.
42
Mortaz E, Bezemer G, Alipoor SD, et al. Nutritional impact and its potential consequences on COVID-19 severity. Front Nutr 2021; 8: 698617.
43
Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients. J Infect 2020; 80(6): e14-8.
44
Lee JY, Kim HA, Huh K, et al. Risk factors for mortality and respiratory support in elderly patients hospitalized with COVID-19 in Korea. J Korean Med Sci 2020; 35(23): e223.
45
Hosseini Damiri SF, Rezai MS, Bagheri-Nesami M, Moosazadeh M. Admission rate and factors associated with COVID-19 Disease in children attending the emergency department in hospitals affiliated to mazandaran university of medical sciences, 2019-2020. J Mazandaran Univ Med Sci 2022; 31(206): 78-89.
46
Jamalinik M, Haddadi M, Abedi A, Tajabadi A, Ganjloo J, Hasheminik M. COVID-19; Symptoms, transmission methods, care and treatment techniques based on the latest evidence available: A narrative review study. Salamat-i Kar-i Iran 2020; 17: 1-14.
47
Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA 2020; 323(11): 1061-9.
48
Yu P, Zhu J, Zhang Z, Han Y. A familial cluster of infection associated with the 2019 novel coronavirus indicating possible person-to-person transmission during the incubation period. J Infect Dis 2020; 221(11): 1757-61.
49
Liu K, Chen Y, Wu D, Lin R, Wang Z, Pan L. Effects of progressive muscle relaxation on anxiety and sleep quality in patients with COVID-19. Complement Ther Clin Pract 2020; 39: 101132.
50
Su L, Ma X, Yu H, et al. The different clinical characteristics of corona virus disease cases between children and their families in China – the character of children with COVID-19. Emerg Microbes Infect 2020; 9(1): 707-13.
51
Iranpour P, Ghaderian Jahromi M. Radiologic manifestations of pulmonary and cardiovascular complications of COVID-19: A narrative review. Majallah-i Ilmi-i Danishgah-i Ulum-i Pizishki-i Rafsanjan 2021; 20(3): 339-52.
52
Iodice F, Cassano V, Rossini PM. Direct and indirect neurological, cognitive, and behavioral effects of COVID-19 on the healthy elderly, mild-cognitive-impairment, and Alzheimer’s disease populations. Neurol Sci 2021; 42(2): 455-65.
53
Arab S, Ebrahimi Z, Izadi A, Madanchi H, Yarmohammadi M, Darban M. Relationship between the history of kidney disease, clinical findings, hospitalization duration, and mortality in COVID-19 patients. Koomesh J 2022; 24(1): 102-8.
54
Aggarwal S, Garcia-Telles N, Aggarwal G, Lavie C, Lippi G, Henry BM. Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): Early report from the United States. Diagnosis 2020; 7(2): 91-6.
55
Salari A, Mahdavi-Roshan M, Ghorbani Z, et al. An investigation of risk factors of in-hospital death due to COVID-19: A case-control study in Rasht, Iran. Ir J Med Sci 2021; 190(4): 1321-33.
56
Firoozi D, Haqqani M, Javadan Sirat S, Paymard A, Ghadimi Moghadam AK. Investigation of the prevalence of underlying diseases in Covid-19 patients in Yasuj. Armaghane Danesh 2021; 25(1, Corona Special Issue): 937-44.
57
Daoust JF. Elderly people and responses to COVID-19 in 27 Countries. PLoS One 2020; 15(7): e0235590.
58
Zaki N, Alashwal H, Ibrahim S. Association of hypertension, diabetes, stroke, cancer, kidney disease, and high-cholesterol with COVID-19 disease severity and fatality: A systematic review. Diabetes Metab Syndr 2020; 14(5): 1133-42.
59
Sun Y, Koh V, Marimuthu K, et al. Epidemiological and clinical predictors of COVID-19. Clin Infect Dis 2020; 71(15): 786-92.
60
Valaei N, Kosaryan M, Nasiri E, Mossavi S. Methodological evaluation of the papers published in the journal of Mazandaran university of medical sciences, number 1-47, summer 2005. J Mazandaran Univ Med Sci 2006; 16(52): 131-40.
61
Shafiei G, Barati E, Zarei AP, et al. The value of chest CT scan as a prognostic tool in patients with COVID-19. Sarem Journal of Reproductive Medicine 2021; 6(1): 53-60.
62
Caspi G, Dayan A, Eshal Y, et al. Socioeconomic disparities and COVID-19 vaccination acceptance: A nationwide ecologic study. Clin Microbiol Infect 2021; 27(10): 1502-6.
63
Sheikh S, Hatami F, Shojaei D, Shams A, Sourani R. The Principles Of Treatment Staff Care Of Elderly Patients Under Burn & Plastic Surgery And With Covid-19 In ICU & Operating Room Based On Clinical Points: The Original Article. J Pharmaceutical Negative Result 2022; 13: 1967-83.
64
Fang Y, Zhang H, Xu Y, Xie J, Pang P, PJi W. CT manifestations of two cases of 2019 novel coronavirus (2019-nCoV) pneumonia Radio 2020; 295(1): 208-9.
65
Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x. Clinical characteristics of coronavirus disease 2019 in China New England J Med 2020; 382(18): 1708-20.